Impact of Monetary Policy Uncertainty on R&D Investment Smoothing Behavior of Pharmaceutical Manufacturing Enterprises: Empirical Research Based on a Threshold Regression Model

Abstract

R&D investment is the source of technological innovation of pharmaceutical enterprises, but it will be restricted by the funding level, especially in the context of major public health emergencies occurring more frequently, therefore exploring the impact of monetary policy uncertainty on the R&D investment smoothing behavior of pharmaceutical manufacturing enterprises has important theoretical and practical value. Based on the relevant data of Chinese pharmaceutical manufacturing enterprises from 2012 to 2018, this paper studies the impact of monetary policy uncertainty on R&D investment smoothing behavior of pharmaceutical enterprises, and investigates whether there is a threshold effect. First, our results demonstrate that the empirical test results of this article support the hypothesis of R&D investment smoothing behavior of pharmaceutical manufacturing enterprises. Second, there is a negative correlation between monetary policy uncertainty and R&D investment smoothing behavior, and the shorter the period is, the higher the financing constraints of pharmaceutical enterprises are, and the more obvious the negative correlation is. Third, financing constraints have a single threshold effect on the R&D investment smoothing behavior of pharmaceutical manufacturing enterprises, with a threshold of −13.7693. Moreover, this conclusion can better promote the virtuous circle of the real economy of financial and pharmaceutical manufacturing enterprises. It is recommended that pharmaceutical manufacturing enterprises establish and improve the enterprise R&D reserve system, reduce the risk of R&D investment, play the role of R&D smoothing, and realize the sustainable development of enterprise R&D.

The Impact of Compensation Gap on Corporate Innovation: Evidence from China’s Pharmaceutical Industry

“…The pharmaceutical industry can obtain high profits on the basis of patents or proprietary technologies, and is typically driven by innovation. Product research and technological innovation are the driving force behind the continuous development of this industry [1]. Corporate technological innovation is a complex process with high risk and a long duration [8].…”

“…It is typically driven by innovation, and is relevant to people's wellbeing. Its innovative development is not only conducive to maintaining the competitive advantages of pharmaceutical enterprises, and enhancing their own values, but also necessary for improving people's living quality [1]. A handful of developed countries remain the source of innovation in the global pharmaceutical industry [2].…”

CEO Overconfidence, Corporate Governance, and R&D Smoothing in Technology-Based Entrepreneurial Firms

“…First, we add to the body of research on the antecedents of TBEFs' R&D smoothing from the upper echelons theoretical perspective, which provides an understanding of the differences in TBEFs' intertemporal dynamic adjustment behavior regarding R&D investments. The impact on R&D smoothing from organizational and contingent perspectives has been explored in the literature (Brown and Petersen, 2011 ; Shin and Kim, 2011 ; Liu et al, 2021 ; Yang et al, 2021 ). However, CEOs are usually the key decision-makers at firms.…”

The Impact of the Consistency Evaluation Policy of Generic Drugs on R&D Investment Intensity of Pharmaceutical Companies—An Empirical Study Based on the Difference-in-Differences Model

“…Based on existing research ( 29 – 32 ), we selected seven factors that may affect the R&D investment of pharmaceutical firms as control variables, among them, the enterprise market competitiveness is represented by the industry Lerner index. Rojas ( 33 ) once stated that the Lerner index is an important indicator representing competitiveness because it specifies the monopoly position of an enterprise in the market.…”